GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parmax Pharma Ltd (BOM:540359) » Definitions » Other Income (Expense)

Parmax Pharma (BOM:540359) Other Income (Expense) : ₹-3.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Parmax Pharma Other Income (Expense)?

Parmax Pharma's other income expense for the Parmax Pharma's pretax income for the three months ended in Dec. 2024 was ₹0.1 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₹-3.0 Mil.

Parmax Pharma Other Income (Expense) Historical Data

The historical data trend for Parmax Pharma's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parmax Pharma Other Income (Expense) Chart

Parmax Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.47 -4.60 -3.72 -3.72 -4.03

Parmax Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 -4.37 0.08 1.17 0.13

Parmax Pharma Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-3.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parmax Pharma  (BOM:540359) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Parmax Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parmax Pharma Ltd (BOM:540359) » Definitions » Other Income (Expense)
Comparable Companies
BOM:524768 NSE:SAROJA BOM:531210 BOM:531015 BOM:523620 BOM:531521 BOM:524752 BOM:524606 BOM:531762 BOM:524516 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Rajkot-Gondal National Highway No. 27, Plot No. 20, Survey No. 52, Taluka Kotda Sangani, Hadamtala, Rajkot, GJ, IND, 360 311
Website
https://www.parmaxpharma.com
Parmax Pharma Ltd is a pharmaceutical company. The company manufactures and sells Tablets, Capsules, Ointments, and injectables. Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Paliperidone, Lacosamide, 2-Acetyl Benzo(B) Thiophene, Camphor Sulfonyl Chloride, 3-Methoxy Thiophene, Silodosin API, and others.

Parmax Pharma Headlines

No Headlines